< News, Press, & Events

Press Release

Genomenon Recognized by Frost & Sullivan for Genomic Intelligence Solutions and Software for Pharma and Clinical Diagnostics Companies

Ann Arbor, MI and San Antonio, TX – May 8, 2023

Frost and Sullivan Names Genomenon its 2023 Global Innovation Leader in Genomics

  • Frost and Sullivan recognizes Genomenon as best-in-class in the genomic industry for genomic search engine, Mastermind
  • Genomenon’s unique blend of its AI-powered platform and tech-enabled scientific expertise delivers actionable insights into the genetic drivers of disease

Frost & Sullivan announced that it has named Genomenon® the winner of its 2023 Global Technology Innovation Leadership Award for its AI-driven genomic search engine and tech-enabled genetic expertise. Genomenon’s groundbreaking technology delivers actionable insight into the genomic drivers of genetic diseases and oncology for drug development and clinical diagnosis.

This annual award given by Frost & Sullivan recognizes the company that has developed a product with innovative features and functionality and is gaining rapid acceptance in the market.

Genomenon creates innovative solutions for both clinical diagnostic and pharmaceutical clients helping both groups navigate genomic intelligence for rare genetic diseases and oncology. Clinical diagnostic labs rely on Genomenon’s Mastermind Genomic Search Engine to find critical information to diagnose genetic diseases and identify the most appropriate patient treatment options. For pharmaceutical clients, the Genomenon scientific team leverages information in the Mastermind knowledgebase to support every stage of clients’ precision medicine pipeline, from biomarker discovery and translational testing to clinical trials and commercialization.

Tejashri Khadilkar, Frost & Sullivan industry analyst commented,

“Genomenon empowers rare disease pharmaceutical and biotechnology companies to make informed decisions about promising candidates in their pipeline and help propel novel therapeutics to market. Its commitment to innovation and creativity, scientific rigor, and accuracy, while achieving commercial success, differentiates it from competitors.”

Mike Klein, Genomenon CEO stated, “This exciting award celebrates the uniqueness of our best-in-class genetic expertise with our market-leading genomic search engine, Mastermind. These two assets enable us to drive actionable genomic insights that can save and improve the lives of those impacted by rare diseases and cancer. This award by Frost and Sullivan further validates our innovative technology for both clinical diagnostic and pharmaceutical clients and leadership in the genomics industry.”

In 2020 Frost and Sullivan awarded Genomenon as “Company of the Year”, recognizing its proven genomics methodology, interpretation and technology.

Read the complete award report here.

About Frost and Sullivan Best Practice
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.


Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.

Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Read the Article
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.